Siga Technologies INC Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Siga Technologies INC (SIGA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 284.20 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-03-10
- Siga Technologies INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 305.44K shares, a 452.38% increase year-over-year.
- Siga Technologies INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 40.08K shares, a 32.43% decline year-over-year.
- Siga Technologies INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 40.08K shares, a 32.43% decline year-over-year.
- Siga Technologies INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-06-30 was 55.30K shares, a 51.98% increase year-over-year.
- Siga Technologies INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 284.20K shares, a 484.28% increase from fiscal 2024.
- Siga Technologies INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 48.64K shares, a 48.93% increase from fiscal 2023.
- Siga Technologies INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 32.66K shares, a 87.83% increase from fiscal 2022.
- Siga Technologies INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 17.39K shares, a 41.79% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | 284.20K shares 10-K · filed 2026-03-10 | |||
| 2025-09-30 | 274.73K shares 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 305.44K shares 10-Q · filed 2025-08-05 | 255.63K shares 10-Q · filed 2025-08-05 | ||
| 2025-03-31 | 40.08K shares 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | 48.64K shares 10-K · filed 2026-03-10 | |||
| 2024-09-30 | 40.08K shares 10-Q · filed 2025-11-06 | 51.52K shares 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | 55.30K shares 10-Q · filed 2025-08-05 | 57.30K shares 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | 59.31K shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 32.66K shares 10-K · filed 2026-03-10 | |||
| 2023-09-30 | 59.31K shares 10-Q · filed 2024-11-07 | 42.24K shares 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | 36.38K shares 10-Q · filed 2024-08-01 | 33.56K shares 10-Q · filed 2024-08-01 | ||
| 2022-12-31 | 17.39K shares 10-K · filed 2025-03-11 | |||
| 2022-09-30 | 32.18K shares 10-Q · filed 2023-11-07 | 12.90K shares 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | 51.93K shares 10-Q · filed 2023-08-08 | 53.35K shares 10-Q · filed 2023-08-08 | ||
| 2021-12-31 | 29.87K shares 10-K · filed 2024-03-12 | |||
| 2020-12-31 | 1.12M shares 10-K · filed 2023-03-02 | |||
| 2020-09-30 | 1.21M shares 10-Q · filed 2021-11-04 | 1.15M shares 10-Q · filed 2021-11-04 | ||
| 2013-12-31 | 0.00 shares 10-K · filed 2014-03-10 | |||
| 2012-12-31 | 0.00 shares 10-K · filed 2014-03-10 | |||
| 2011-12-31 | 504.67K shares 10-K · filed 2014-03-10 | |||
| 2010-12-31 | 0.00 shares 10-K/A · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |